Cyltezo(adalimumab-adbm), the First Interchangeable Biosimilar to Humira
The US FDA has approved the first interchangeable biosimilar product to treat…
Blenrep (belantamab mafodotin), new option for the treatment of relapsed and refractory multiple myeloma
EMA’s human medicines committee (CHMP) has recommended granting a conditional…